Inventor · disambiguated record
Charles E. Murry
Also filed as: MURRY CHARLES · MURRY CHARLES E
8 granted patents·17 pending applications·53 citations·filing 2004–2024
82Inventor score
Files withUNIV WASHINGTON17SANA BIOTECHNOLOGY INC4MURRY CHARLES E1REGNIER MICHAEL1UNIV WASHINGTON CT COMMERCIALI1
Top patents by PatentIndex Score
25 records- 0193US7875451B2Formulation to improve survival of transplanted cellsUNIV WASHINGTON·Filed 2006·Granted Jan 25, 2011·25 cites·18 claims
- 0287US9994812B2Systems and method for engineering muscle tissueUNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION·Filed 2013·Granted Jun 12, 2018·21 cites·14 claims
- 0374US9868937B2Cell and gene based methods to improve cardiac functionREGNIER MICHAEL·Filed 2012·Granted Jan 16, 2018·6 cites·18 claims
- 0471US2025121038A1Nucleic acid encoding rrm2 subunit of ribonucleotide reductase to resist degradationUNIV WASHINGTON·Filed 2024·Application pending·0 cites
- 0569US11331027B2System for magnetic detection of myocardial forcesUNIV WASHINGTON·Filed 2017·Granted May 17, 2022·1 cites·22 claims
- 0666US2025145957A1Generation of deoxyadenosine triphosphate donor cells and uses thereofUNIV WASHINGTON·Filed 2024·Application pending·0 cites
- 0765US2025241965A1Method to improve cell viability of cardiomyocytesUNIV WASHINGTON·Filed 2023·Application pending·0 cites
- 0862US2023293581A1Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 0962US2022049226A1Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 1060US2023250393A1Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmiaUNIV WASHINGTON·Filed 2023·Application pending·0 cites
- 1158US12208133B2Engineering the RRM2 subunit of ribonucleotide reductase to resist degradationUNIV WASHINGTON·Filed 2019·Granted Jan 28, 2025·0 cites·10 claims
- 1258US12060579B2Human pluripotent stem cell derived endocardial endotheliumUNIV WASHINGTON·Filed 2020·Granted Aug 13, 2024·0 cites·13 claims
- 1356US2025101382A1Genetically modified cells and compositions and uses thereofSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1455US2024226178A1Electrophysiological modification to suppress arrhythmiasUNIV WASHINGTON·Filed 2022·Application pending·0 cites
- 1555US2025082689A1Compositions and methods for enhancing cardiomyocyte transplant engraftmentUNIV WASHINGTON·Filed 2022·Application pending·0 cites
- 1654US2024189481A1Non-contractile cardiomyocytes for cardiac repairUNIV WASHINGTON·Filed 2022·Application pending·0 cites
- 1752US2022152117A1Methods of promoting cellular maturation with ampk activatorsUNIV WASHINGTON·Filed 2020·Application pending·0 cites
- 1851US11752176B2Methods and compositions for enhancing cardiomyocyte maturation and engraftmentUNIV WASHINGTON·Filed 2018·Granted Sep 12, 2023·0 cites·15 claims
- 1951US10612002B2Human pluripotent stem cell derived endocardial endotheliumUNIV WASHINGTON·Filed 2017·Granted Apr 7, 2020·0 cites·8 claims
- 2049US2024122990A1Compositions and methods for cardiomyocyte transplantationUNIV WASHINGTON·Filed 2022·Application pending·0 cites
- 2148US2022296572A1Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositionsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2247US2016015860A1Micro-tissue particles and methods for their use in cell therapyUNIV WASHINGTON CT COMMERCIALI·Filed 2013·Application pending·0 cites
- 2343US2023077983A1Methods of treating and preventing engraftment arrhythmiasUNIV WASHINGTON·Filed 2021·Application pending·0 cites
- 2443US2022152278A1Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdownUNIV WASHINGTON·Filed 2020·Application pending·0 cites
- 2543US2006040389A1Purified compositions of stem cell derived differentiating cellsMURRY CHARLES E·Filed 2004·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →